← Leaderboards
Bonnie Ky
University Of Pennsylvania
$11,886,775
Attributed
$13,452,032
Total exposure
11
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2010–25$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$13,452,032 · 11
By mechanism
R01$9,776,414 · 4
R21$1,841,073 · 4
R34$756,810 · 1
K23$703,846 · 1
K24$373,889 · 1
Top collaborators
- Justin Bekelman4 shared
- Jinbo Chen2 shared
- Kenneth Ber Margulies2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Tomoko None Ohnishi$3,063,647
- Deirdre Sawinski$3,763,593
- Ronald Koder$1,747,585
- Trevor M. Penning$29,812,455
- P Leslie Dutton$10,229,444
Others in their field
Top investigators on “Heart Failure”
- Judith S Hochman · New York University School Of Medicine$120,321,606
- David T Mauger · Pennsylvania State Univ Hershey Med Ctr$51,947,333
- Lisa P Jacobson · Johns Hopkins University$45,397,923
- Walter N Kernan · Yale University$42,197,025
- Dalane W Kitzman · Wake Forest University$40,701,149
- David Couper · Univ Of North Carolina Chapel Hill$37,959,091
Research focus
Heart FailureCardiovascular SystemCardiotoxicityMalignant NeoplasmsCohort StudiesCancer PatientHeartBiological MarkersMortalityPhenotypeFunctional DisorderCardiomyopathiesCancer TherapyCardiovascular Risk FactorCardiacMorbidity - Disease RateOncologyCessation Of LifeStressBreast Cancer PatientUniversitiesPennsylvaniaRadiation TherapyBiological
Grant awards (34)
Cardiovascular Risk Prediction and Reduction in Men with Prostate Cancer$716,697
R01 · FY2025 · HL · contact PI
MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGY$123,507
K24 · FY2025 · HL · contact PI
Cardiovascular Risk Prediction and Reduction in Men with Prostate Cancer$21,775
R01 · FY2025 · HL · contact PI
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity$738,037
R01 · FY2024 · HL · contact PI
MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGY$124,608
K24 · FY2024 · HL · contact PI
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity$751,612
R01 · FY2023 · HL · contact PI
Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer$397,439
R01 · FY2023 · HL · contact PI
MENTORING IN PATIENT-ORIENTED RESEARCH IN DEEP PHENOTYPING IN CARDIO-ONCOLOGY$125,774
K24 · FY2023 · HL · contact PI
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity$725,518
R01 · FY2022 · HL · contact PI
Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer$396,254
R01 · FY2022 · HL · contact PI
Long Term Effects of Breast Cancer Therapy on Cardiac Remodeling and Function$203,125
R21 · FY2022 · HL · contact PI
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity$728,209
R01 · FY2021 · HL · contact PI
Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer$405,461
R01 · FY2021 · HL · contact PI
Long Term Effects of Breast Cancer Therapy on Cardiac Remodeling and Function$243,750
R21 · FY2021 · HL · contact PI
Strategies in Cardiotoxicity Risk Reduction with Breast Cancer Therapy$206,996
R21 · FY2021 · HL · contact PI
The Feasibility of a Biomarker Guided Strategy in Anthracycline Cardiotoxicity$206,593
R21 · FY2021 · HL · contact PI
Mechanistic Risk Prediction of Radiation Therapy Cardiotoxicity$762,918
R01 · FY2020 · HL · contact PI
Markers of Cardiotoxicity with Radiation Therapy in Breast Cancer$436,078
R01 · FY2020 · HL · contact PI
Planning Grant for CARISMA - Cancer therapy Risk-reduction with Intensive Systolic BP Management$371,449
R34 · FY2020 · HL · contact PI
Strategies in Cardiotoxicity Risk Reduction with Breast Cancer Therapy$257,238
R21 · FY2020 · HL · contact PI
The Feasibility of a Biomarker Guided Strategy in Anthracycline Cardiotoxicity$254,763
R21 · FY2020 · HL · contact PI
Planning Grant for CARISMA - Cancer therapy Risk-reduction with Intensive Systolic BP Management$385,361
R34 · FY2019 · HL · contact PI
Markers of Oxidative and Nitrosative Stress in Anthracycline Cardiotoxicity and Statin Cardioprotection$118,786
R21 · FY2019 · HL · contact PI
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity$678,320
R01 · FY2018 · HL · contact PI
Markers of Oxidative and Nitrosative Stress in Anthracycline Cardiotoxicity and Statin Cardioprotection$349,822
R21 · FY2018 · HL · contact PI
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity$722,340
R01 · FY2017 · HL · contact PI
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity$758,005
R01 · FY2016 · HL · contact PI
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity$747,668
R01 · FY2015 · HL · contact PI
Multimarker Risk Prediction in Cancer Therapy Cardiotoxicity$790,083
R01 · FY2014 · HL · contact PI
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure$139,674
K23 · FY2014 · HL · contact PI
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure$140,754
K23 · FY2013 · HL · contact PI
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure$139,997
K23 · FY2012 · HL · contact PI
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure$140,645
K23 · FY2011 · HL · contact PI
The Role of Neuregulin in Human Cardiac Remodeling and Heart Failure$142,776
K23 · FY2010 · HL · contact PI